A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of subcutaneous Mircera for
correction of anemia in participants with chronic kidney disease who are not treated with
erythropoiesis stimulating agent (ESA) and not on dialysis. Eligible participants will
receive Mircera by monthly subcutaneous injections. The initial dose, based on body weight,
will be 1.2 micrograms/kilogram (mcg/kg). The anticipated time on study treatment is 9-11
months, and the target sample size is 100-500 individuals.